CDH2 and esophageal cancer: To study whether the effects of PI3K/AKT inhibition on esophageal cancer cell motility were associated with changes in E-cadherin and N-cadherin expressions, the esophageal cancer cells transfected with PTEN or treated with PI3K/AKT inhibitors were analyzed by Western blot.